01 — The Text
What.
- Extends federal funding for ALS drug research and development programs through fiscal year 2031.
- Requires NIH and FDA to track safety data on experimental drugs and report serious side effects promptly.
- Directs FDA to publish a five-year action plan for developing and approving new ALS and neurodegenerative disease treatments.
- Maintains public-private partnerships between FDA and NIH to speed up therapy development and regulatory review.
02 — The Stakes
So what?
- ALS patients gain continued access to experimental drugs and faster pathways to new treatments for a progressive, fatal disease.
- Researchers and biotech companies get predictable funding and clearer FDA guidance, reducing uncertainty in drug development investments.
- Public health agencies must be more transparent about treatment safety and development progress, improving accountability.
- People ineligible for clinical trials remain able to access investigational drugs through federally-funded research programs.
03 — The Path
Now what?
- House passed it July 22. Senate received it July 23 and has it on the calendar for debate—typical timing is weeks to months.
- Senate must vote on the bill; bipartisan support (103 cosponsors) makes passage likely but not guaranteed.
- Contact your senator to express support if ALS research matters to you; track Senate action at Congress.gov.
Legislative History
Actions.
- Jul 23, 2026 — Received in the Senate. Read twice. Placed on Senate Legislative Calendar under General Orders. Calendar No. 466.
- Jul 22, 2026 — Motion to reconsider laid on the table Agreed to without objection.
- Jul 22, 2026 — On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote.
- Jul 22, 2026 — Passed/agreed to in House: On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote.
- Jul 22, 2026 — Considered as unfinished business. (consideration: CR H5159)
- Jul 20, 2026 — At the conclusion of debate, the chair put the question on the motion to suspend the rules. Mr. Guthrie objected to the vote on the grounds that a quorum was not present. Further proceedings on the motion were postponed. The point of no quorum was considered as withdrawn.
- Jul 20, 2026 — DEBATE - The House proceeded with forty minutes of debate on H.R. 8205.
- Jul 20, 2026 — Considered under suspension of the rules. (consideration: CR H4652-4654; text: CR H4653)